SEC Form SC 13G/A filed by Cyclerion Therapeutics Inc. (Amendment)

2/9/24 8:50:19 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $CYCN alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.4 CYCLERION THERAPEUTICS INC COMMON STOCK Cusip #23255M204 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #23255M204 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 162,819 Item 6: 0 Item 7: 162,849 Item 8: 0 Item 9: 162,849 Item 11: 6.660% Item 12: HC Cusip #23255M204 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 162,849 Item 8: 0 Item 9: 162,849 Item 11: 6.660% Item 12: IN Item 1(a). Name of Issuer: CYCLERION THERAPEUTICS INC Item 1(b). Address of Issuer's Principal Executive Offices: 301 Binney Street Cambridge, MA 02142 USa Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 23255M204 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 162,849 (b) Percent of Class: 6.660% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 162,849 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of CYCLERION THERAPEUTICS INC. No one other person's interest in the COMMON STOCK of CYCLERION THERAPEUTICS INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification Fidelity Management & Research Company LLC IA Fidelity Management Trust Company BK Strategic Advisers LLC IA Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on February 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of CYCLERION THERAPEUTICS INC at December 29, 2023. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $CYCN alert in real time by email

Date

Price Target

Rating

Analyst

10/20/2021

$14.00

Buy

Truist Securities

9/24/2021

$7.00

Overweight

Cantor Fitzgerald

SEC Form SC 13G/A filed by Cyclerion Therapeutics Inc. (Amendment)

2/9/24 8:50:19 AM ET

$CYCN

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $CYCN alert in real time by email

Date

Price Target

Rating

Analyst

10/20/2021

$14.00

Buy

Truist Securities

9/24/2021

$7.00

Overweight

Cantor Fitzgerald

SEC Form SC 13G/A filed by Cyclerion Therapeutics Inc. (Amendment)

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$CYCN

SEC Form SC 13G/A filed by Cyclerion Therapeutics Inc. (Amendment)

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$CYCN

$CYCN
Press Releases

Cyclerion's sGC Stimulator Portfolio Generates Revenues to Enable Company Growth

Regina Graul, Ph.D., Promoted to Chief Executive Officer

Cyclerion Appoints Regina Graul, Ph.D., as President

$CYCN
Analyst Ratings

Truist Securities initiated coverage on Cyclerion Therapeutics with a new price target

Cantor Fitzgerald initiated coverage on Cyclerion Therapeutics with a new price target

$CYCN
SEC Filings

Amendment: SEC Form SCHEDULE 13G/A filed by Cyclerion Therapeutics Inc.

SEC Form 10-Q filed by Cyclerion Therapeutics Inc.

SEC Form 8-K filed by Cyclerion Therapeutics Inc.

$CYCN
Insider Trading

SEC Form 4 filed by Chief Financial Officer Chicko Rhonda M.

Director Hecht Peter M was granted 181,818 shares, increasing direct ownership by 48% to 559,203 units (SEC Form 4)

Director Higgins Michael J was granted 9,090 shares, increasing direct ownership by 42% to 30,740 units (SEC Form 4)

$CYCN
Leadership Updates

Cyclerion Appoints Regina Graul, Ph.D., as President

Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial Results

Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics' Board of Directors

$CYCN
Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by Cyclerion Therapeutics Inc.